Practice Trends in the Treatment of Actinic Keratosis in the United States: 0.5% Fluorouracil and Combination Cryotherapy plus Fluorouracil are Underused despite Evidence of Benefit
Restricted accessResearch articleFirst published online March, 2012
Practice Trends in the Treatment of Actinic Keratosis in the United States: 0.5% Fluorouracil and Combination Cryotherapy plus Fluorouracil are Underused despite Evidence of Benefit
Topical fluorouracil and cryotherapy are among the most commonly used treatments for actinic keratosis. Evidence shows that 0.5% fluorouracil has similar efficacy and is better tolerated than 5% fluorouracil. Evidence also shows that combination therapy with cryosurgery and fluorouracil is beneficial.
Objective:
To examine fluorouracil and cryotherapy use in the treatment of actinic keratosis.
Methods:
The National Ambulatory Medical Care Survey database was queried for visits for actinic keratosis. Visits were analyzed for patient demographics, provider specialty, and treatment regimens. Fluorouracil and cryotherapy use was analyzed over time.
Results:
Cryotherapy was the most commonly used treatment for actinic keratosis. Fluorouracil products were prescribed to 1.1 million patients (6.6%) between 2001 and 2008; of these, dermatologists prescribed 0.5% fluorouracil in 51.8% of cases and 5% fluorouracil in 38.9% of cases. Combination fluorouracil and cryotherapy was used for only 1.1% of actinic keratosis visits between 1993 and 2008 and was never used by nondermatologists.
Conclusions:
Despite evidence suggesting comparable efficacy, greater tolerability, and lower cost of 0.5% fluorouracil relative to 5% fluorouracil, 5% fluorouracil is used by dermatologists almost as often as 0.5% fluorouracil. Among nondermatologists, 5% fluorouracil is used exclusively. Combination therapy of fluorouracil and cryotherapy is underused despite evidence of its benefit.
MoyRL.Clinical presentation of actinic keratoses and squamous cell carcinoma. J Am Acad Dermatol2000;42:42-8, doi:10.1067/mjd.2000.103343.
5.
GlogauRG.The risk of progression to invasive disease. J Am Acad Dermatol2000;42:42-23, doi:10.1067/mjd.2000.103339.
6.
MollerR, ReymannF, Hou-JensenHou-Jensen.Metastases in dermatological patients with squamous cell carcinoma. Arch Dermatol1979;115:115-703, doi:10.1001/archderm.1979.04010060011017.
7.
SmithES, FeldmanSR, FleischerABJr. Characteristics of office-based visits for skin cancer. Dermatologists have more experience than other physicians in managing malignant and premalignant skin conditions. Dermatol Surg1998;24:24-981, doi:10.1016/S1076-0512(98)00095-8.
8.
FeldmanSR, FleischerABJr, WillifordPM, JorizzoJL.Destructive procedures are the standard of care for treatment of actinic keratoses. J Am Acad Dermatol1999;40:40-43, doi:10.1016/S0190-9622(99)70526-8.
9.
GrahamGF.Advances in cryosurgery during the past decade. Cutis1993;52:52-365.
10.
JorizzoJ, StewartD, BuckoA. Randomized trial evaluating a new 0.5% fluorouracil formulation demonstrates efficacy after 1-, 2-, or 4-week treatment in patients with actinic keratosis. Cutis2002;70:70-335.
11.
McIntyreWJ, DownsMR, BedwellSA.Treatment options for actinic keratoses. Am Fam Physician2007;76:76-667.
12.
BalkrishnanR, CayceKA, KulkarniAS. Predictors of treatment choices and associated outcomes in actinic keratoses: results from a national physician survey study. J Dermatolog Treat2006;17:17-162, doi:10.1080/09546630600765081.
13.
LovenK, SteinL, FurstK, LevyS.Evaluation of the efficacy and tolerability of 0.5% fluorouracil cream and 5% fluorouracil cream applied to each side of the face in patients with actinic keratosis. Clin Ther2002;24:24-990, doi:10.1016/S0149-2918(02)80012-1.
14.
JorizzoJL, CarneyPS, KoWT. Fluorouracil 5% and 0.5% creams for the treatment of actinic keratosis: equivalent efficacy with a lower concentration and more convenient dosing schedule. Cutis2004;74:74-18.
15.
LevyS, FurstK, ChernW.A pharmacokinetic evaluation of 0.5% and 5% fluorouracil topical cream in patients with actinic keratosis. Clin Ther2001;23:23-908, doi:10.1016/S0149-2918(01)80078-3.
16.
KaurRR, AlikhanA, MaibachHI.Comparison of topical 5-fluorouracil formulations in actinic keratosis treatment. J Dermatolog Treat2010;21:21-267, doi:10.3109/09546630903341937.
17.
WeinstockMA, BinghamSF, ColeGW. Reliability of counting actinic keratoses before and after brief consensus discussion: the VA Topical Tretinoin Chemoprevention (VATTC) trial. A novel 0.5% fluorouracil cream is minimally absorbed into the systemic circulation yet is as effective as 5% fluorouracil cream. Arch Dermatol2001;137:137-1055.
18.
YentzerBA, AdeRA, FountainJM. Simplifying regimens promotes greater adherence and outcomes with topical acne medications: a randomized controlled trial. Cutis2010;86:86-103.
19.
GuptaAK.The management of actinic keratoses in the United States with topical fluorouracil: a pharmacoeconomic evaluation. Cutis2002;70:70-30.
20.
JorizzoJ, WeissJ, FurstK. Effect of a 1-week treatment with 0.5% topical fluorouracil on occurrence of actinic keratosis after cryosurgery: a randomized, vehicle-controlled clinical trial. Arch Dermatol2004;140:140-813, doi:10.1001/archderm.140.7.813.
21.
JorizzoJ, WeissJ, VamvakiasG.One-week treatment with 0.5% fluorouracil cream prior to cryosurgery in patients with actinic keratoses: a double-blind, vehicle-controlled, long-term study. J Drugs Dermatol2006;5:5-133.
22.
LeeAD, JorizzoJL.Optimizing management of actinic keratosis and photodamaged skin: utilizing a stepwise approach. Cutis2009;84:84-169.
23.
FleischerABJr, FeldmanSR, BradhamDD.Office-based physician services provided by dermatologists in the United States in 1990. J Invest Dermatol1994;102:102-93, doi:10.1111/1523-1747.ep12371739.
24.
FleischerABJr, FeldmanSR, WhiteRE. Procedures for skin diseases performed by physicians in 1993 and 1994: analysis of data from the National Ambulatory Medical Care Survey. J Am Acad Dermatol1997;37:37-719, doi:10.1016/S0190-9622(97)70107-5.
25.
AliottaSL, VlasnikJJ, DelorB.Enhancing adherence to long-term medical therapy: a new approach to assessing and treating patients. Adv Ther2004;21:21-214, doi:10.1007/BF02850154.
26.
VermeireE, HearnshawH, Van RoyenP, DenekensJ.Patient adherence to treatment: three decades of research. A comprehensive review. J Clin Pharm Ther2001;26:26-331, doi:10.1046/j.1365-2710.2001.00363.x.
FeldmanSR, CamachoFT, Krejci-ManwaringJ. Adherence to topical therapy increases around the time of office visits. J Am Acad Dermatol2007;57:57-81, doi:10.1016/j.jaad.2007.04.005.
29.
Krejci-ManwaringJ, TusaMG, CarrollC. Stealth monitoring of adherence to topical medication: adherence is very poor in children with atopic dermatitis. J Am Acad Dermatol2007;56:56-211, doi:10.1016/j.jaad.2006.05.073.
30.
WilsonR, CamachoF, ClarkAR. Adherence to topical hydrocortisone 17-butyrate 0.1% in different vehicles in adults with atopic dermatitis. J Am Acad Dermatol2009;60:60-166, doi:10.1016/j.jaad.2008.09.031.
31.
YentzerB, HickJ, WilliamsL. Adherence to a topical regimen of 5-fluorouracil, 0.5%, cream for the treatment of actinic keratoses. Arch Dermatol2009;145:145-203, doi:10.1001/archdermatol.2008.562.
32.
FeldmanSR.Practical ways to improve patients' treatment outcomes. Winston Salem (NC): Medical Quality Enhancement Corporation;2009.
33.
FeldmanSR.Approaching psoriasis differently: patient-physician relationships, patient education and choosing the right topical vehicle. J Drugs Dermatol2010;9:9-908.
34.
PaivaEF, RochaAT.[How to implement a guideline from theory to practice: the example of the venous thromboembolism prophylaxis]. Acta Med Port2009;22:22-21.
